Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly

NCT ID: NCT04803513

Last Updated: 2021-03-17

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 300 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-11-01
• Study Completion Date: 2022-08-31

Brief Summary

Objective: To determine in real life the efficacy, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chronic (CM) migraine.

Design: This prospective observational cohort study was conducted between November 2019 and January 2021.

Participants: Consecutive adult HFEM and CM patients clinically prescribed galcanezumab were enrolled.

Setting: Multicenter study in 13 Italian headache centers.

Exposure: Galcanezumab subcutaneous injection 120 mg monthly with the first loading dose of 240 mg.

Main Outcome(s) and Measure(s): The primary end-point was the change in monthly migraine days (MMDs) in HFEM patients and monthly headache days (MHDs) in CM ones after six months of therapy (V6) compared to baseline. Secondary end-points included variation in Numerical Rating Scale (NRS), monthly painkiller intake (MPI), HIT-6, and MIDAS scores. We assessed 50%, 75%, and 100% responder rates (RR), the conversion rate from CM to episodic migraine (EM), and the Medication Overuse condition to the non-overuser.

Detailed Description

GARLIT is an independent, multicenter, prospective, cohort, real-life study. All consecutive patients aged 18 or older with a diagnosis of HFEM (8-14 migraine days per month) or CM (1.3 ICHD-3), who had failed at least three migraine preventive treatments and not previously involved in any CGRP mAbs trial, are considered for enrolment. Patients are assessed at baseline by a headache expert neurologist with a face-to-face interview using a semi-structured questionnaire addressing socio-demographic factors, clinical migraine features, previous and current acute and preventive migraine treatments, comorbidities and concomitant medications. Headache-related dopaminergic and autonomic symptoms, temporal artery turgidity/hyperpulsatility, and allodynia during or between attacks are also investigated. Patients are also requested to rate the overall efficacy of triptans in most attacks as none/poor (0) or fair/excellent (1).

Enrolled patients will carefully fill in a headache diary during a run-in month period (baseline) and the entire duration of the study, to report monthly migraine days (MMDs) for HFEM patients, all monthly headache days (MHDs) of at least moderate intensity for CM subjects, and monthly painkillers intake (MPI). Patients were also asked to rate pain severity (using the 0-10 Numerical Rating Scale, NRS) of the worst painful attack and fill in migraine disability questionnaires (Headache Impact Test, HIT-623, monthly, and the MIgraine Disability Assessing Scale24, MIDAS, quarterly).

Patients will be treated with galcanezumab subcutaneous injection with the first loading dose of 240mg and then every month with 120mg as recommended, according to real life clinical indication (www.europa.ema.eu).

The above-reported variables and any adverse event (AE) are recorded at baseline and monthly at every in-office visits. Telephone/email contacts are allowed when in-office visits are not possible. All AEs are reported to Eudravigilance and classified as gastrointestinal (e.g. nausea, constipation), cutaneous (e.g. injection-site reactions: rash/erythema, pruritus, urticaria, oedema/induration), arthralgia, Raynaud phenomenon, dizziness and other (<1% of patients: i.e. somnolence, alopecia, anxiety).

Patients will provide written informed consent.

Conditions

Migraine

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Galcanezumab

Galcanezumab according to clinical indication in real life

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• the clinical indication for Galcanezumab as a preventive treatment for Migraine according to European Medicines Agency
• age18 years or older
• 8 or more mean Monthly Migraine Headache days in the last three months

Exclusion Criteria

• previous exposure to any monoclonal antibodies inhibiting CGRP pathway, including clinical trials

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Campus Bio-Medico University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fabrizio Vernieri, MD

Role: PRINCIPAL_INVESTIGATOR

Campus Bio-Medico University

Locations

Campus Bio Medico University Hospital

Rome, RM, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Fabrizio Vernieri, MD

Role: CONTACT

f.vernieri@unicampus.it

003922541 ext. 1889

Claudia Altamura, MD PhD

Role: CONTACT

c.altamura@unicampus.it

003962251 ext. 1270

Facility Contacts

Fabrizio Vernieri, MD

Role: primary

c.altamura@gmail.com

+3906 ext. 1889

References

Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Schiano Di Cola F, d'Onofrio F, Finocchi C, Bertuzzo D, Bono F, Ranieri A, Albanese M, Messina R, Doretti A, Di Piero V, Cevoli S, Barbanti P, Vernieri F; GARLIT Study Group. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022 Nov;269(11):5848-5857. doi: 10.1007/s00415-022-11226-4. Epub 2022 Jun 28.

Reference Type: DERIVED

PMID: 35763113 (View on PubMed)

Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. 2022 Apr;29(4):1198-1208. doi: 10.1111/ene.15197. Epub 2021 Dec 6.

Reference Type: DERIVED

PMID: 34826192 (View on PubMed)

Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021 May 3;22(1):35. doi: 10.1186/s10194-021-01247-1.

Reference Type: DERIVED

PMID: 33941080 (View on PubMed)

Other Identifiers

IRB Number

Identifier Type: REGISTRY

Identifier Source: secondary_id

GARLIT

Identifier Type: -

Identifier Source: org_study_id